Formulation of Chitosan-Coated Brigatinib Nanospanlastics: Optimization, Characterization, Stability Assessment and In-Vitro Cytotoxicity Activity Against H-1975 Cell Lines
March 2022
in “
Pharmaceuticals
”
TLDR The new Brigatinib nanocarrier is more effective against lung cancer cells than the free drug.
The study developed and optimized chitosan-coated Brigatinib-loaded nanospanlastics (NSPs) for enhanced delivery and efficacy against H-1975 lung cancer cell lines. The optimal formulation (S13) achieved high entrapment efficiency and stable vesicle size, with chitosan coating improving drug retention and release. In vitro studies showed the NSPs had significantly higher cytotoxicity compared to free Brigatinib, enhancing anticancer efficacy by 3 to 4 times. Stability tests confirmed the formulation's robustness over three months, suggesting that chitosan-coated NSPs could improve Brigatinib's therapeutic outcomes in non-small cell lung cancer treatment.
